Cabaletta Bio Issues Inducement Equity Grants to Four New Hires
Cabaletta Bio awarded inducement equity grants to four newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4).
Cabaletta Bio, Inc. (Nasdaq: CABA), a Philadelphia-based late-stage clinical biotechnology company specializing in targeted cell therapies for autoimmune diseases, disclosed on Oct. 5, 2026, that it had granted inducement equity awards to four newly hired non-executive employees.
The grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4), a provision that allows companies to issue equity compensation as a material inducement to prospective employees joining the firm without requiring a full shareholder vote. Such awards are a common mechanism biotechnology companies use to attract specialized talent in a competitive hiring environment.
Read more CRMLS Files Lawsuit Against Compass Over MLS Policy Dispute →
Calabetta Bio describes itself as focused on developing curative cell therapies designed specifically for patients suffering from autoimmune conditions, a therapeutic area that has attracted significant industry investment in recent years. Recruiting qualified personnel is widely viewed as a critical factor in advancing late-stage clinical programs toward potential regulatory approval.
The company did not disclose the specific number of shares, strike prices, or vesting terms associated with the individual grants in its announcement. Inducement grant disclosures under Nasdaq rules require public notice but do not mandate the full financial detail typically found in proxy filings.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
